Exploring New and Emerging Oral Treatments in HR-Positive, HER2-Negative Breast Cancer: A Primer for Health-System Pharmacists

This activity was originally presented at the 2022 ASHP Midyear Clinical Meeting & Exposition.

Program Description

CDK4/6 inhibitors are emerging as an important addition to the adjuvant treatment armamentarium for patients with HR-positive/HER2-negative breast cancer. Regrettably, patients with cancer receiving oral therapies, such as CDK4/6 inhibitors, experience more challenges with at-home administration and treatment nonadherence due to lack of interaction with the health care team. Health-system and oncology pharmacists can bridge important gaps in the care of patients by helping mitigate challenges associated with oral treatment with CDK4/6 inhibitors through personalized treatment and management strategies that consider patient access issues, the cost of therapy, tolerability of medications, patient education, self-management, and monitoring and follow-up. This program will review clinical data supporting therapeutic combination and sequencing strategies with CDK4/6 inhibitors in an effort to help patients with advanced or metastatic HR-positive/HER2-negative breast cancer to improve survival outcomes. Differences among available CDK4/6 inhibitors will also be discussed. Patient case reviews will examine considerations for treatment sequencing as well as disease- and patient-specific factors that influence treatment selection of CDK4/6 inhibitors. Strategies for proactive management of drug therapy with CDK4/6 inhibitors in order to mitigate toxicities and optimize therapeutic outcomes will also be reviewed.

Target audience: Health-system and oncology pharmacists

Type of activity: Application
Release date: December 22, 2022
Expiration date: December 22, 2023

Time to complete activity: 1.5 hours
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Differentiate new and emerging oral therapies in the treatment of HR-positive/HER2-negative breast cancer by pharmacology, safety, and pearls for use in clinical practice
• Apply guideline recommendations and drug therapy knowledge to individualize treatment selection for a patient with HR-positive/HER2-negative breast cancer
• Determine strategies to mitigate adverse effects associated with treatment of HR-positive/HER2-negative metastatic breast cancer

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-22-618-H01-P. The activity is available for CE credit through December 22, 2023.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Heather N. Moore, PharmD, BCOP, CPP, has the following financial relationships with commercial interests to disclose:
Consultant: Lilly, Novartis, AstraZeneca, Daiichi Sankyo

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Danielle Roman, PharmD, BCOP

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Amy H. Seung, PharmD, BCOP, FHOPA; Evelina Kolychev, PharmD; Abigail Dill; Susan Pordon; Brianna Winters; and Chloe Taccetta.

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms